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ABSTRACT
Purpose
To provide consensus recommendations on the use of
epidermal growth factor receptor tyrosine kinase in-
hibitors (EGFR-TKIs) in patients with advanced or meta-
static non-small-cell lung cancer (NSCLC).
Methods
Using a systematic literature search, phase II trials,
randomized phase III trials, and meta-analyses were
identified for inclusion.
Results
A total of forty-six trials were included. Clear evidence
is available that EGFR-TKIs should not be administered
concurrently with platinum-based chemotherapy as
first-line therapy in advanced or metastatic NSCLC.
Evidence is currently insufficient to recommend sin-
gle-agent EGFR-TKIs as first-line therapy either in
unselected populations or in populations selected on
the basis of molecular or clinical characteristics. Fol-
lowing failure of platinum-based chemotherapy, the
evidence suggests that second-line EGFR-TKIs or sec-
ond-line chemotherapy result in similar survival. Quality
of life and symptom improvement for patients treated
with an EGFR-TKI appear better than they do for pa-
tients treated with second-line docetaxel. Sequence of
therapy may not appear to be important, but if survival
is the outcome of interest, the goal should be to optimize
the number of patients receiving three lines of therapy.
Based on available data, molecular markers and clini-
cal characteristics do not appear to be predictive of a
differential survival benefit from an EGFR-TKI and
therefore those factors should not be used to select
patients for EGFR-TKI therapy.
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Conclusions
The EGFR-TKIs represent an additional therapy in the
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1. INTRODUCTION
Lung cancer represents a major health burden in
Canada. Approximately 23,300 new lung cancer cases
and 19,900 deaths from lung cancer occurred in 2007,
most of which were non-small-cell lung cancer
(NSCLC)1. Most of these patients either present with or
develop metastatic disease at some point during their
illness; potentially, they are candidates for systemic
therapy approaches such as chemotherapy.
Until the late 1990s, therapeutic nihilism about the
benefit of systemic chemotherapy in the treatment of
advanced and metastatic NSCLC was widespread. Pub-
lication of the Non-small Cell Lung Cancer Collabo-
rative Group meta-analysis in 1995 established the
association of first-line platinum-based chemotherapy
with a modest improvement in survival for patients with
metastatic disease 2. The introduction of newer drugs
such as vinorelbine, gemcitabine, paclitaxel, and
docetaxel have resulted in further small improvements,
although most patients still experience disease progres-
sion within a short time, with a median time to pro-
gression (TTP) of approximately 4 months 3–5.
At the time of progression following platinum-
based chemotherapy, many patients maintain a goodPRACTICE GUIDELINE SERIES
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performance status (PS) and may be candidates for
further systemic therapy. Recent trials have established
that second-line chemotherapy with docetaxel 6–9 im-
proves survival and quality of life (QOL) as compared
with best supportive care (BSC) and that survival of
patients treated with docetaxel or pemetrexed is simi-
lar 10. Guidelines for the management of NSCLC, in-
cluding those from Cancer Care Ontario’s Program
in Evidence-Based Care (CCO-PEBC) 11 now recom-
mend either of those agents as second-line chemo-
therapy options 11,12.
Despite these advancements in the treatment of
NSCLC, there is still a strong need for additional and
better treatment options. Recently, a greater under-
standing of the molecular abnormalities associated
with NSCLC has led to evaluation of new therapeutic
targets for NSCLC. The epidermal growth factor
receptor (EGFR) is one target commonly overexpressed
in NSCLC 13–15. Early-phase clinical trials showed that
EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib
and gefitinib had antitumour activity, and this finding
prompted their further evaluation in advanced NSCLC 16.
These agents have been evaluated extensively in
phase II and III trials over the last few years, confirm-
ing the promising activity seen in phase I trials, and
the TKIs have been incorporated into treatment algo-
rithms for patients after progression on standard
chemotherapy options 11.
Because of a favourable toxicity profile of the
TKIs, many clinicians felt that it might be appropriate
to expand their role in the treatment of advanced and
metastatic NSCLC. A need therefore exists to clarify
the role of EGFR-TKIs in the treatment of NSCLC. The
present paper represents a consensus view of a rep-
resentative sample of Canadian lung cancer medical
oncologists on the role of EGFR-TKIs in the treatment
of NSCLC based on a systematic review of currently
available evidence.
2. MATERIALS AND METHODS
Medical oncologists specializing in thoracic oncology
from five provinces across Canada were invited to
participate in a consensus meeting. Six oncologists at-
tended the consensus meeting, and three additional
oncologists, plus one pathologist, provided input into
the consensus process. Three key questions were iden-
tified to be addressed by the group:
￿ What is the role of EGFR-TKIs as first-line therapy
of advanced or metastatic NSCLC as a single agent
or in combination with chemotherapy?
￿ What is the role of EGFR-TKIs following progres-
sion after platinum-based chemotherapy (single-
agent EGFR-TKI vs. BSC, EGFR-TKI vs. chemotherapy,
and EGFR-TKI in combination with another agent)?
￿ Do any patient subpopulations, or clinical and mo-
lecular characteristics, predict for additional ben-
efit from EGFR-TKI therapy?
2.1 Literature Search
A search of the MEDLINE database for 2000–2007 was
conducted using the terms “non-small-cell lung can-
cer,” “epidermal growth factor receptor tyrosine ki-
nase inhibitor,” “erlotinib,” and “gefitinib.” The search
excluded articles prior to 2000, because the EGFR-TKIs
are new agents and their initial phase I trials were
known to be conducted during the selected time pe-
riod. Conference proceedings of the American Society
of Clinical Oncology 2000–2007 and the International
Association for the Study of Lung Cancer 2007 World
Conference on Lung Cancer were also searched. Fi-
nally, the list of included articles was reviewed by the
consensus panel for omissions.
2.2 Study Selection Criteria
Articles published as full reports or as abstracts and con-
ference presentations were included if they focused on
￿ EGFR-TKI alone or in combination with chemo-
therapy in the first-line setting,
￿ EGFR-TKI as second- or third-line therapy follow-
ing progression of platinum-based chemotherapy,
or
￿ clinical and molecular characteristics that may
predict additional benefit from EGFR-TKI therapy.
The literature search results were reviewed by two
authors (PE, FK), and articles that met the foregoing
criteria were selected for retrieval. The outcomes of
interest were overall survival (OS), time to disease pro-
gression, tumour response rate, molecular and clinical
predictors of benefit from EGFR-TKI therapy, and QOL
or symptom improvement. Single-arm phase II trials
were included only if no data from randomized trials
were available. Forty-three individual trials (eight phase
III, eleven randomized phase II, and twenty-four sin-
gle-agent phase II trials) met the eligibility criteria for
the present consensus statement. Only studies published
in English were considered.
2.3 External Review
Final consensus statement draft recommendations were
distributed electronically to reviewers. The review
panel consisted of practitioners who had attended the
consensus meeting and others who were not in attend-
ance. The comments resulting from this review were
incorporated into the final document.
3. RECOMMENDATIONS AND KEY EVIDENCE
3.1 First-Line Treatment
What is the role of EGFR-TKIs as first-line therapy of
advanced or metastatic NSCLC as a single agent or in
combination with chemotherapy?ELLIS et al.
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3.1.1 What Is the Role of Single-Agent EGFR-TKIs in
Chemonaïve Patients with NSCLC?
Key Evidence:   Fourteen single-arm phase II trials (n =
1026) and one randomized phase II trial (n = 201) evalu-
ated single-agent erlotinib 150 mg or gefitinib 250 mg
daily as first-line therapy of stage IIIB/IV NSCLC (Ta-
ble I). In general, patients had an Eastern Cooperative
Oncology Group PS of 0–2 and were not selected for
clinical or molecular characteristics reported to be as-
sociated with improved response to an EGFR-TKI. Sub-
stantial variability was observed in the response rate
to single-agent EGFR-TKIs (range: 4%–55%, with an
additional 20%–46% achieving disease stabilization).
The time to disease progression ranged from 1 month
to 6.6 months, with median survival varying between
2.9 months and 14.1 months, and 1-year survival being
24%–58.2% 17–22,24,26,27,30–36,38,39.
A single randomized placebo-controlled trial com-
pared gefitinib to BSC in patients with poor perform-
ance (PS 2–3) unsuitable for chemotherapy. The observed
response rate was only 6%, and the trial failed to dem-
onstrate significant improvement in either TTP or OS 33.
Among the trials in unselected populations, QOL
and symptom improvement data were inconclusive 17–
22,24,26,27,30–36,38,39. In the single randomized trial, the
proportion of patients reporting QOL and symptom im-
provement appeared similar for gefitinib and BSC (21.1%
vs. 20.0% and 28.3% vs. 23.3% respectively) 33. Sev-
eral other authors also reported no significant improve-
ment in QOL over time 24,31. However, Spigel reported
improvement or no change in QOL [using the Func-
tional Assessment of Cancer Therapy–Lung (FACT-L)]
in 82% of patients, and improvement or control in lung
cancer symptom (LCS) response in 48% of patients 19.
Pérez–Soler reported significant improvements in pain
scores at 2 weeks and improvement in emotional func-
tioning during the first 4 weeks of therapy 17 (Table I).
In general, these QOL analyses involved small num-
bers of patients in the absence of control groups and
should be interpreted cautiously.
The remaining five phase II trials selected patients
based on the presence of activating mutations of the
EGFR gene (n = 85) or of clinical characteristics asso-
ciated with high response rate to treatment (n = 40).
The trials included patients with stage III or IV NSCLC
and PS 0–2, and evaluated either erlotinib 150 mg or
gefitinib 250 mg daily. Higher response rates were
observed in these selected populations (range: 30%–
90%) as compared with the unselected populations
described earlier 23,25,28,29,37,40. Longer time to dis-
ease progression was also observed (5.6–13.3 months).
Median survival was 15.4 months in one trial 40 and
was either not reported or not reached in the others
23,25,28,29,37. This activity appears encouraging, but
randomized trials comparing EGFR-TKI therapy to
chemotherapy are needed to draw firm conclusions.
Consensus Recommendation:   The evidence is cur-
rently insufficient to recommend first-line single-agent
EGFR-TKI therapy in the treatment of advanced or
metastatic NSCLC. These recommendations apply both
to unselected populations and to patients selected on
the basis of activating mutations of the EGFR gene or
of clinical characteristics predictive of higher response
to therapy.
There is evidence of tumour response to single-
agent EGFR-TKI as first-line therapy for advanced
NSCLC. Response rates to EGFR-TKI therapy appear to
be higher in patients selected on the basis of activating
mutations of the EGFR gene.
Randomized trials are needed to evaluate the ef-
fect of first-line EGFR-TKI on survival.
3.1.2 What Is the Role of Single-Agent EGFR-TKIs in
Patients with Adenocarcinoma with Bronchioloalveolar
Features?
Key Evidence:   The literature search identified a con-
sensus document on systemic therapy of bronchi-
oloalveolar carcinoma (BAC) 41. It states that there is
no evidence to confirm or refute the assertion that the
sensitivity of BAC to chemotherapy is any different from
that of other histologic subtypes of NSCLC.
Three phase II trials in PS 0–2 patients with stage
III/IV BAC (n = 326) evaluated either erlotinib 150 mg
or gefitinib 250 mg daily (Table II). Patients were pre-
dominantly chemotherapy-naïve. Response rates
ranged from 9% to 21%, with disease stabilization in
an additional 16%–36%. The survival data demon-
strated time to disease progression of between 3.0
months and 3.7 months, and median survival of 13.0–
17.1 months 42–45. In one study, shorter progression-
free survival (PFS) and OS were independently
associated with non-mucinous as compared with mu-
cinous BAC (PFS: 2.6 months vs. 11.3 months, p=0.002;
OS: 10.7 months vs. not reached, p = 0.003)44,45.
Consensus Recommendation:   There is no evidence
to suggest that BAC should be treated differently from
other types of NSCLC. The evidence is currently insuf-
ficient to recommend EGFR-TKIs as first-line therapy
for the treatment of BAC.
3.1.3 What Is the Role of First-Line EGFR-TKIs in
Combination with Platinum-based Chemotherapy in
Patients with NSCLC?
Key Evidence:   Four large randomized trials evaluated
EGFR-TKIs in combination with platinum-based chemo-
therapy in patients with good PS with stage III/IV NSCLC
(n = 4348, Table III). Patients were treated with either
gemcitabine and cisplatin [gemcitabine 1250 mg/m2
intravenously (IV) on days 1 and 8, and cisplatin 80
mg/m2 IV on day 1 of a 21-day cycle] or carboplatin
and paclitaxel [carboplatin area under the curve (AUC)
6 IV on day 1, and paclitaxel 200 mg/m2 IV on day 1
of a 21-day cycle] with or without erlotinib 150 mg or
gefitinib 250 mg or 500 mg daily. Response rates var-PRACTICE GUIDELINE SERIES
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ied between the trials; however, all four trials failed to
demonstrate any improvement in response rate with
the addition of an EGFR-TKI to platinum-based chemo-
therapy 46–49. Time to worsening of symptoms did not
differ significantly between the groups 46,47,49.
No differences were observed in time to disease
progression or in median and 1-year survival between
patients randomized to chemotherapy alone and those
randomized to chemotherapy plus an EGFR-TKI 46–49
(see Table III).
Consensus Recommendation:   Clear evidence from
four randomized trials shows that concurrent adminis-
tration of an EGFR-TKI with first-line platinum-based
chemotherapy does not prolong survival in unselected
patients with NSCLC.
3.1.4 What Is the Role of Single-Agent EGFR-TKIs
Compared with Chemotherapy in Chemonaïve Patients
with NSCLC?
Key Evidence:   Two randomized trials compared first-
line therapy with an EGFR-TKI with chemotherapy in
chemonaïve patients with stage III/IV NSCLC and PS
0–2 (n = 299, Table IV) 50,52. Lilenbaum randomized
patients with poor PS (score of 2) to treatment with
either carboplatin and paclitaxel (carboplatin AUC 6
and paclitaxel 200 mg/m2 for 4 cycles) or erlotinib
150 mg daily 52; Crinò randomized elderly patients
(more than 70 years of age) to vinorelbine 30 mg/m2 IV
on days 1 and 8 of a 21-day cycle or gefitinib 250 mg
daily 50.
Lilenbaum observed a higher response rate among
patients treated with chemotherapy than with erlotinib
[overall response (OR): 12% vs. 2%; OR + stable dis-
ease (SD): 53% vs. 39%]. Additionally, patients
randomized to carboplatin–paclitaxel had a longer time
to progression (3.5 months vs. 1.9 months) and a greater
survival (9.1 months vs. 6.6 months), although these
differences were not statistically significant 52.
Crinò observed similar activity from vinorelbine
and gefitinib (OR: 5.1% vs. 3.1%; OR+SD: 53% vs. 43%).
The PFS favoured vinorelbine, but this difference was
not statistically significant [hazard ratio (HR): 1.19; 95%
confidence interval (CI): 0.85 to 1.65]. No difference
in overall survival was observed (HR: 0.98; 95%CI: 0.66
to 1.47). The groups showed no difference in overall
QOL (by FACT-L) and in LCS. Gefitinib appeared to be
better tolerated than vinorelbine 50.
A third trial evaluated various doses and schedules
of erlotinib with carboplatin and paclitaxel 51. No sig-
nificant differences were observed among the three
treatment groups (Table IV).
Consensus Recommendation:  The evidence is cur-
rently insufficient to recommend the use of an EGFR-
TKI over chemotherapy in the first-line therapy of patients
with NSCLC. Available evidence raises the possibility
that survival of patients with poor PS treated with first-
line EGFR-TKI may be less than that of patients treated
with platinum-based chemotherapy.
3.2 Second-Line and Subsequent Treatment for
Relapsed or Recurrent Disease
What is the role of EGFR-TKIs following progression
after platinum-based chemotherapy (single-agent EGFR-
TKI vs. BSC, EGFR-TKI vs. chemotherapy, and EGFR-
TKI in combination with another agent)?
3.2.1 What Is the Role of EGFR-TKIs as Second- or Third-
Line Therapy Following Progression of Platinum-based
Chemotherapy?
Key Evidence:  Two guidelines developed by CCO-PEBC,
addressing the role of an EGFR-TKI as subsequent
therapy for NSCLC, were identified 11,53. Both docu-
ments recommend the use of erlotinib as second- or
third-line therapy for NSCLC in patients who are not
candidates for further chemotherapy.
Four randomized phase II and III trials in PS 0–2
patients with stage III/IV NSCLC who were not consid-
ered candidates for further chemotherapy examined
EGFR-TKIs as subsequent therapy following progres-
sion of platinum-based chemotherapy (n = 2849, Table
V). Two large phase III studies evaluated erlotinib 150
mg (BR.21) or gefitinib 250 mg [ISEL (Iressa Survival
Evaluation in Lung Cancer)] daily compared with pla-
cebo 56,57, and two randomized phase II studies [IDEAL
1 and 2 (Iressa Dose Evaluation in Advanced Lung
Cancer 1 and 2)] compared two doses of gefitinib (250
or 500 mg daily) 54,55. In the IDEAL 1 and 2 trials, no
differences were observed in any outcomes examined
between gefitinib 250 mg and 500 mg daily.
Results of the BR.21 and ISEL trials demonstrated
that erlotinib (2.2 months vs. 1.8 months) and gefitinib
(3.0 months vs. 2.6 months) significantly prolong time
to disease progression 56,57. Statistically significant im-
provements were also seen in OS with erlotinib as com-
pared with placebo (6.7 months vs. 4.7 months, p <
0.001) 56, and a trend toward improved survival was
observed with gefitinib (5.6 months vs. 5.1 months, p =
0.087) 57.
In the BR.21 trial, patients receiving erlotinib ex-
perienced significantly longer time to deterioration in
several lung cancer-related symptoms (cough, pain,
dyspnea) and in overall physical function 58. In the ISEL
trial, a greater proportion of patients randomized to
gefitinib experienced improvement in disease-related
symptoms (27% vs. 22%). Similarly, patients
randomized to gefitinib experienced a significantly
greater improvement in LCS scores (–1.38 vs. –0.86,
p = 0.019) 57.
Consensus Recommendation:   In patients with ad-
vanced or metastatic NSCLC who are not candidates
for further chemotherapy, the use of an EGFR-TKI (asPRACTICE GUIDELINE SERIES
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compared with placebo) can result in improved sur-
vival. The use of an EGFR-TKI in patients with NSCLC
who are not candidates for further chemotherapy can
result in significant improvements in disease-related
symptoms, and as compared with BSC alone, can delay
time to symptom progression.
3.2.2 What Is the Role of EGFR-TKIs Compared with
Chemotherapy Following Progression of Platinum-based
Chemotherapy?
Key Evidence:   Seven randomized phase II and III tri-
als examined an EGFR-TKI as compared with chemo-
therapy following progression of platinum-based
chemotherapy in patients with stage III/IV NSCLC and
PS 0–2 (n = 2482, Table VI).
One randomized phase II trial 59 and two randomized
phase III trials 62,65,66 evaluated gefitinib 250 mg daily
vs. docetaxel 60 or 75 mg/m2 IV every 3 weeks (n =
2096). The response rate with gefitinib was significantly
higher than that with docetaxel in a Japanese population
(22.5% vs. 12.8%, p = 0.009) 65,66. However no differ-
ences were observed in response rate between gefitinib
and docetaxel in the other two trials 59,62. No significant
differences were observed in TTP or OS in patients treated
with gefitinib or docetaxel. In the trial by Niho et al., the
proportion of patients randomized to docetaxel who re-
ceived third-line EGFR-TKI therapy was greater than the
proportion of patients randomized to gefitinib who re-
ceived third-line chemotherapy. That trial did not meet
its primary outcome of non-inferiority of gefitinib (up-
per limit of 95% CI ≤ 1.25) as compared with docetaxel
(HR: 1.12; 95% CI: 0.89 to 1.40) 65,66. However, the larger
INTEREST trial (Iressa non-small-cell lung cancer trial
evaluating response and survival against Taxotere)  dem-
onstrates that gefitinib was non-inferior to docetaxel (HR:
1.02; 95% CI: 0.905 to 1.15), in which the definition of
non-inferiority accepted a CI going up to 1.154 62. The
proportion of patients receiving effective third-line
therapy was similar between the two treatment arms in
that trial.
Another four randomized phase II studies evalu-
ated gefitinib 250 mg or erlotinib 150 mg daily with
other agents (oral vandetanib 300 mg daily 60;
bortezomib 1.6 mg/m2 IV on days 1 and 8 of a 21-day
cycle 64; vinorelbine 15 mg/m2 IV on day 1, and gefitinib
250 mg daily on days 2–14 every 2 weeks 61;
bevacizumab 15 mg IV on day 1 every 3weeks;
docetaxel 75 mg/m2 on day 1 of a 3-week cycle;
pemetrexed 500 mg/m2 on day 1 of a 3-week cycle) 63
either as single agents or in combination (n = 386, Ta-
ble VI). No firm conclusions can be drawn from any of
these trials, although compared with erlotinib alone,
the combination of erlotinib plus bevacizumab demon-
strated improvement in response rate (17.9% vs.
12.2%), TTP (4.4 months vs. 3.0 months), and OS (13.7
months vs. 8.6 months) 63. A phase III trial of that com-
bination is ongoing. Fully powered phase III trials are
ongoing to compare gefitinib with vandetanib and to
assess whether bevacizumab adds to the efficacy of
single-agent erlotinib.
Consensus Recommendation:   The evidence suggests
that second-line EGFR-TKI or second-line chemotherapy
results in similar survival. Sequence does not appear
to be important, but if survival is the outcome of inter-
est, the goal should be to optimize the number of pa-
tients receiving three lines of effective therapy. The
evidence is currently insufficient to recommend sec-
ond-line therapy with a combination of an EGFR-TKI
and another targeted agent. Ongoing randomized phase
III trials are currently addressing these questions.
3.2.3 How Do QOL and Symptom Control Compare in
Patients Treated with Chemotherapy as Compared with
EGFR-TKIs?
Key Evidence:   Two of the three trials that compared
gefitinib and docetaxel also examined QOL and symp-
tom improvement 59,62.
In the SIGN trial (Second-Line Indication of
Gefitinib in NSCLC), a greater proportion of patients
randomized to gefitinib experienced symptom improve-
ment as assessed by LCS (36.8% vs. 26%) and QOL
improvement as assessed by the FACT-L (33.8% vs.
26%) 59. In addition, in the INTEREST trial, significantly
more patients randomized to the gefitinib arm showed
improvements in FACT-L score (25.1% vs. 14.7%, p <
0.0001) and trial outcome index (17.3% vs. 10.3%, p =
0.0026). Symptom improvement rates were also bet-
ter with gefitinib than with docetaxel, but this differ-
ence was not statistically significant 62.
Key Recommendation:   Symptom control and QOL
appear to be better in patients treated with an EGFR-
TKI than in those treated with either BSC or second-
line chemotherapy with docetaxel. In decisions about
treatment following failure of platinum-based chemo-
therapy, QOL and patient choice are important.
3.2.4 What Is the Role of Single-Agent EGFR-TKI Therapy
in Previously Treated Patients with EGFR Gene Mutations
or High Gene Copy, or EGFR Protein Expression?
Key Evidence:  Four single-arm phase II trials evalu-
ated gefitinib 250 mg daily in patient populations (n =
117) selected for the presence of activating mutations
of the EGFR gene assessed by polymerase chain reac-
tion (PCR) analysis or for high EGFR gene copy as-
sessed using fluorescence in situ hybridization (FISH).
Patients had stage III/IV disease and PS 0–2, and most
had received prior chemotherapy. High response rates
were observed (48%–90%) 67–70. Time to disease
progression ranged from 6.4 months to 12.9 months,
with a median survival of 15.5 months reported in one
study 69. Given that EGFR mutations are thought to
represent a favourable prognostic factor, the signifi-
cance of these data are unclear, and randomized trialsPRACTICE GUIDELINE SERIES
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are needed to determine if the survival of patients with
EGFR mutations or high EGFR gene copy treated with
an EGFR-TKI is superior to that of similar patients treated
with second-line chemotherapy.
Consensus Recommendations:   There is evidence that
patients with previously treated NSCLC and EGFR mu-
tations or increased EGFR gene copy respond to an EGFR-
TKI. However, the evidence is insufficient at this time
to select patients for EGFR-TKI therapy rather than for
second-line chemotherapy based on any EGFR marker.
3.3 Clinical and Molecular Predictors of Benefit
Do any patient subpopulations, or clinical and molecu-
lar characteristics, predict for additional benefit from
EGFR-TKI therapy?
3.3.1 What Are the Molecular Characteristics that
Predict Additional Benefit from EGFR-TKI Therapy?
Key Evidence:   Clinical Predictors of Response to an
EGFR-TKI:   Table VII summarizes the trials examin-
ing clinical predictors of response. Data are available
from the IDEAL 1, IDEAL 2, BR.21, and ISEL trials. Analy-
ses from the IDEAL 1 and 2 trials demonstrated that ad-
enocarcinoma (13% vs.4%) and female sex (19% vs.
3%) both significantly predict response to gefitinib 55.
Additional clinical predictors of response were ob-
served in the BR.21 trial. In that study, clinical char-
acteristics associated with higher response to erlotinib
included adenocarcinoma (13.9% vs. 4.1%, p < 0.001),
never smokers (24.7% vs. 3.9%, p < 0.001), female sex
(14.4% vs. 6%, p = 0.006), and Asian ethnicity (n = 427:
18.9% vs. 7.5%, p = 0.002) 56,71–73. Consistent with the
BR.21 results, subset analysis from the ISEL trial also
demonstrated that adenocarcinoma (11.9% vs. 4.8%),
never smokers (18.1% vs. 5.3%), female sex (14.7%
vs. 5.1%), and Asian ethnicity (12.4% vs. 7.5%) were
predictors of response to gefitinib (n = 1439) 57.
Clinical Predictors of Survival with an EGFR-TKI:
Table VIII summarizes clinical predictors of survival
for patients receiving therapy with an EGFR-TKI 57,71–
79. In the BR.21 trial, the only clinical characteristic
that predicted greater effect on survival for erlotinib as
compared with supportive care alone was a history of
never having smoked (HR: 0.4 vs. 0.9; p = 0.02). There
was no evidence of any differential survival effect for
histology (HR: 0.7 adenocarcinoma vs. 0.8 non-adeno-
carcinoma), sex (HR: 0.8 males vs. 0.8 females), or
ethnicity (HR: 0.6 Asian vs. 0.8 non-Asian) 71–73,77,78.
The ISEL trial demonstrated significantly improved
survival among patients randomized to gefitinib for
never smokers (HR: 0.67; 95% CI: 0.49 to 0.92) and for
patients of Asian ethnicity (HR: 0.66; 95%CI: 0.48 to
0.91) 57. There was a trend toward improved survival
for patients with adenocarcinoma treated with gefitinib
(HR: 0.84; 95% CI: 0.70 to 1.02). In a subset analysis of
all Asian patients from the ISEL trial, significant im-
provements in survival were seen for patients with ad-
enocarcinoma (HR: 0.66 vs. 0.86), never smokers (HR:
0.37 vs. 0.85), and female sex (HR: 0.46 vs. 0.80) 76.
No data were available concerning clinical pre-
dictors of survival from the INTACT (Iressa NSCLC Trial
Assessing Combination Treatment) 1 and 2 trials 80. In
a subset analysis of never smokers (n = 113) from the
TRIBUTE (Tarceva Responses in Conjunction with
Paclitaxel and Carboplatin) trial, a significant improve-
ment in survival was observed from the addition of
erlotinib (HR: 0.49; 95% CI: 0.28 to 0.85) 81. Similar
findings were observed in TALENT (Tarceva Lung Can-
cer Investigation Trial). Improved OS and PFS were
observed for patients receiving erlotinib who had never
smoked (HR: 0.39; p = 0.25), although this interaction
did not achieve statistical significance 74,75.
In contrast, subgroup analyses from the INTEREST
trial comparing gefitinib with docetaxel suggest that
these clinical variables do not predict a differential
benefit for an EGFR-TKI over chemotherapy. There was
no difference in the survival of patients with adenocar-
cinoma histology, never smokers, Asian ethnicity, and
female sex when treated with either gefitinib or
docetaxel 79.
Molecular Predictors of Response to an EGFR-TKI:   The
predictive value of various molecular abnormalities
have been examined in the randomized trials included
in the present consensus document. These include
mutations of the EGFR gene, increased EGFR gene
copy assessed by FISH or EGFR amplification assessed
by quantitative PCR, EGFR expression [by immunohis-
tochemistry (IHC)], and mutations of the KRAS gene.
Table IX summarizes predictors of response.
The presence of an activating mutation of the EGFR
gene is associated with an increased likelihood of re-
sponse to single-agent EGFR-TKI. Analyses of tumour
samples from the IDEAL 1 and 2 trials (n = 425) evalu-
ating gefitinib monotherapy demonstrated that patients
whose tumour had an EGFR mutation had a better OR
with gefitinib than did patients lacking the mutation (n =
79: 46% vs.10%, p = 0.005) 80. In the BR.21 (n = 177:
15.8% vs. 7.4%, p = 0.35) and ISEL trials (n = 215:
37.5% vs. 2.6%), the presence of an EGFR mutation
was associated with a nonsignificant increase in re-
sponse rate. In BR.21, when only exon 19 deletion and
L858R mutations were considered, the difference in
response rate as compared with wild-type EGFR or other
mutations was significant (27% vs. 7%, p = 0.035) 85.
The subset analysis of tumour samples from the IN-
TACT 1 and 2 trials evaluating the addition of gefitinib
to standard first-line chemotherapies demonstrated that
patients whose tumours had an EGFR mutation had a
higher response to chemotherapy plus gefitinib than did
those without a mutation (n = 170: 72% vs. 55%, p =
0.2) 80. Similar findings were observed in the TRIBUTE
trial for patients with EGFR mutations (n = 228: 53%
vs. 21%, p < 0.01) 82,84, but no statistically significantPRACTICE GUIDELINE SERIES
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TABLE VII   Trials of clinical characteristics that predict response from therapy with epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs)
      Reference Study Patients Treatment Adenocarcinoma Never smokers Female sex Asian ethnicity
(n)
Kris et al., 2003 55 IDEAL 2 216 Gefitinib 250 mg daily 13% vs. 4% 19% vs. 3%
vs. gefitinib 500 mg daily
Shepherd et al., 2005 56 BR.21 731 Erlotinib 150 mg daily n=427 n=427 n=427 n=427
Clark et al., 2006 71,a vs. placebo 13.9% vs. 4.1% 24.7% vs. 3.9% 14.4% vs. 6% 18.9% vs. 7.5%
Florescu et al., 2006 72 p<0.001 p<0.001 p=0.006 p=0.002
Tsao et al., 2006 73
Thatcher et al., 2005 57 ISEL 1439 Gefitinib 250 mg daily n=1439 n=1439 n=1439 n=1439
vs. placebo 11.9% vs. 4.8% 18.1% vs. 5.3% 14.7% vs. 5.1% 12.4% vs. 7.5%
ISEL = Iressa Survival Evaluation in Lung Cancer; IDEAL = Iressa Dose Evaluation in Advanced Lung Cancer.
correlation was observed between response rates and
mutation status in the TALENT trial 74,75.
Increased EGFR gene copy or EGFR amplification
also appears to be associated with an increased response
rate to single-agent EGFR-TKI. The IDEAL 1 and 2 trials
demonstrated that EGFR amplification was associated
with a higher response to gefitinib than was seen with
tumours without EGFR amplification; however, this dif-
ference was not statistically significant (n = 90: risk
ratio: 29% vs.15%; p = 0.319). Patients with an EGFR
mutation or gene amplification had a significantly im-
proved response rate as compared with patients with
neither EGFR amplification nor mutation (60% vs.
10%, p = 0.0011) 80. Within the BR.21 trial, high EGFR
gene copy or amplification also was associated with a
significantly higher response to erlotinib (n = 91: 21%
vs. 5%, p = 0.02) 71,77,85. Similar findings were ob-
served in the ISEL trial (n = 317: 16.4% vs. 3.2%) 83.
In INTACT 1 and 2, there were no differences in
response with and without EGFR amplification (n =
235: 56% vs. 53%, p > 0.05) 80. Interestingly, analysis
of tumour samples from the TRIBUTE study demon-
strated a lower response rate among patients whose
tumours demonstrated EGFR amplification 82,84. It is
important to note that FISH was used to assess EGFR
gene copy status in the BR.21, ISEL, and TRIBUTE stud-
ies 82–85, but that quantitative PCR was used in the IDEAL
and INTACT studies 80. High EGFR gene copy by FISH
includes cases of EGFR high polysomy and of EGFR
amplification alike 82–85, but quantitative PCR results
include cases of EGFR gene amplification only 80.
Thus, the two results are not entirely comparable.
Fewer data are available concerning the predic-
tive value of EGFR protein expression. In both the BR.21
(n = 142: 11% vs. 4%, p= 0.1) 85 and ISEL trials (n =
303: 8.2% vs. 3.2%) 83, higher response rates to erlotinib
were demonstrated for patients with EGFR expression.
However, the presence of KRAS mutations appears to
be associated with a lower chance of tumour response.
Lower response rates were observed in the BR.21 (n =
118: 5% vs. 10%, p = 0.069) 85, ISEL (n = 93: 0% vs.
8%) 83, and TRIBUTE trials (n = 264: 8% vs. 23%, p =
0.16) 82,84, although none of those results was statisti-
cally significant.
Molecular Predictors of Survival: Table X summarizes
trials examining molecular predictors of survival for
patients treated with an EGFR-TKI 71,74,75,77,80,82–86.
No single molecular marker has consistently been as-
sociated with improved survival for patients treated with
an EGFR-TKI.
The IDEAL 1 and 2 trials, BR.21, and ISEL all ex-
amined single-agent EGFR-TKIs 71,77,83,85. Analysis of
tumour samples from IDEAL 1 and 2 showed no sig-
nificant improvement in TTP or survival for patients
with EGFR mutations or with EGFR amplification 80.
However, these trials were not designed to examine
predictors of survival, given that both groups of pa-
tients received an EGFR-TKI 80.
The BR.21 trial generated several reports of mo-
lecular analyses 71,77,85. On univariate analyses, there
was no evidence that the survival benefit of erlotinib
was influenced significantly by EGFR expression (n =
325: IHC+ HR: 0.68; IHC– HR: 0.93; p = 0.1), increased
EGFR gene copy (n = 159: FISH+ HR: 0.43; FISH– HR:
0.80; interaction p = 0.12), or EGFR mutation status
(n = 204: mut+ HR: 0.55; mut– HR: 0.74; interaction p =
0.47). However, in multivariate analysis, increased
EGFR gene copy was prognostic for poorer survival
(p = 0.0025) and predictive of a differential survival
benefit from erlotinib (p = 0.005) 71,77,85.
The molecular analysis of the ISEL trial demon-
strated a differential effect of gefitinib on survival ac-
cording to EGFR gene copy (n = 370: FISH+ HR 0.61
vs. FISH– HR 1.16; interaction p = 0.045) and EGFR ex-
pression (n = 379: IHC+  HR: 0.77; IHC–  HR: 1.57;
interaction p = 0.049). The data were insufficient for a
survival analysis for patients with and without EGFR
mutations 83.
Molecular analyses are available from all four tri-
als evaluating the addition of an EGFR-TKI to platinum-
based chemotherapy. The addition of gefitinib toELLIS et al.
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i
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p
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i
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.
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c
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i
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i
n
i
b
 
2
5
0
 
m
g
 
d
a
i
l
y
n
=
3
2
5
n
=
5
7
8
n
=
4
4
7
(
P
o
o
l
e
d
 
s
u
b
s
e
t
v
s
.
 
p
l
a
c
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.
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i
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.
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u
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.
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c
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.
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.
0
2
2
I
n
t
e
r
a
c
t
i
o
n
 
p
=
0
.
7
9
6
a
I
N
T
A
C
T
 
1
:
 
C
h
e
m
o
t
h
e
r
a
p
y
 
(
g
e
m
c
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c
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c
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i
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.
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p
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i
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c
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c
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c
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c
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i
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e
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chemotherapy did not significantly improve OS in pa-
tients with (HR: 2.03; 95% CI: 0.67 to 6.13) or without
(HR: 1.01; 95% CI: 0.79 to 1.29) EGFR amplification
(n = 453), or with (HR: 1.77; 95% CI: 0.5 to 6.2) and
without (HR: 0.91; 95% CI: 0.67 to 1.23) EGFR muta-
tions (n = 312) 86.
Survival analysis from the TRIBUTE trial demon-
strated a borderline improvement in TTP for patients
receiving chemotherapy plus erlotinib (TTP HR: 0.59;
95% CI: 0.35 to 0.99), but no difference in OS for pa-
tients with EGFR amplification (n = 245) 82,84. In pa-
tients with an EGFR mutation, there was also a trend
toward improved TTP (12.5 months vs. 6.6 months, p =
0.092), but no difference in OS was demonstrated (p =
0.96, n = 274) 82,83. Similar findings were observed
in the TALENT study. The presence of EGFR muta-
tions did not predict for improved OS (p = 0.65 for
placebo vs. p = 0.40 for erlotinib) and PFS (p = 0.74
for placebo vs. p = 0.18 for erlotinib) irrespective of
treatment 74,75.
Information is more consistent that the presence
of KRAS mutations is associated with worse survival
for patients receiving an EGFR-TKI. Results from BR.21
demonstrated a trend towards worse survival for pa-
tients on erlotinib with KRAS mutations (n = 206: KRAS+
HR: 1.67; KRAS– HR: 0.69; p = 0.09) 71,77,85. Similarly,
KRAS mutations predicted poor overall survival in
erlotinib-treated patients on the TALENT trial 74,75. In
addition, data from the TRIBUTE trial demonstrated
that the presence of KRAS mutations was associated
with significantly decreased TTP and survival in pa-
tients randomized to erlotinib plus chemotherapy (n =
274: HR: 2.1; 95% CI: 1.1 to 3.8; 4.4 months vs. 13.5
months KRAS+ vs. 12.1 months vs. 11.3 months KRAS–,
p = 0.019] 82,84.
In contrast, there is no evidence that these mo-
lecular markers predict a differential effect on survival
from an EGFR-TKI than from chemotherapy. The mo-
lecular analyses from the INTEREST trial showed no
significant differences in survival between patients
treated with gefitinib or with docetaxel according to
EGFR expression, EGFR gene copy, EGFR mutational
status, or KRAS status 79.
Consensus Recommendation:   Molecular markers
such as EGFR high gene copy or EGFR mutations and
clinical characteristics such as adenocarcinoma, fe-
male sex, never smoking, and Asian ethnicity appear
to be associated with a higher likelihood of response to
an EGFR-TKI. The evidence is currently insufficient to
select patients based on molecular markers predictive
of improved survival with an EGFR-TKI. Prospective
data will be needed before further recommendations
can be made.
The evidence is conflicting about the predictive
value of clinical characteristics for survival. However,
the data suggest that the survival benefit of an EGFR-
TKI may be greater among never smokers. Based on
available data, molecular markers and clinical
characteristics should not be used to exclude patients
from receiving EGFR-TKI therapy.
4. DISCUSSION
The EGFR-TKIs of represent a significant advance in
the management of advanced and metastatic NSCLC.
Not only do they have activity in NSCLC, they also ap-
pear to have an improved toxicity profile as compared
with standard chemotherapy agents such as docetaxel.
As a result, they offer an attractive therapeutic option.
Nevertheless, it is important that these agents be in-
corporated into routine treatment algorithms based on
appropriate data from randomized trials.
It is clear that EGFR-TKIs should not be used con-
comitantly with standard chemotherapy agents in the
treatment of NSCLC. The strongest evidence support-
ing their use is in patients who have progressed fol-
lowing platinum-based chemotherapy. It is appealing
to think that use of an EGFR-TKI may spare patients the
toxicity of more chemotherapy. However, available data
support the use of second-line chemotherapy and third-
line EGFR-TKI or second-line EGFR-TKI and then third-
line chemotherapy. Because both approaches prolong
survival, the goal of therapy in advanced NSCLC should
be to maximize the number of patients who receive
three lines of therapy, if survival is the outcome of in-
terest. However, some patients will choose not to have
second-line chemotherapy, and so the sequence of
therapies should reflect a discussion between the phy-
sician and the patient regarding the relative benefits
and side effects of each treatment option.
Multiple reports in the literature suggest that mo-
lecular markers and clinical characteristics can be used
to select patients who will be more likely to benefit
from an EGFR-TKI. However, this literature comes with
significant limitations. The term “benefit” creates con-
fusion, because it is used to refer to a variety of out-
comes, including tumour response, improved OS, and
improved symptom control and QOL. The molecular
analyses are limited to patients whose tumour sam-
ples were available. The percentage of patients whose
samples were available for one or more molecular
analyses ranged from 25% to 44% of the total study
population. As a result, some of these comparisons in-
volve small numbers of patients. In addition, much of
the literature has focused on tumour response rates,
rather than on survival. Although there is some con-
sistency in factors predicting response, these factors
do not correlate directly with variables predicting a
differential benefit in survival. Considerable varia-
tion is found in the variables reported to be associated
with a differential improvement in survival from therapy
with an EGFR-TKI. This variation may exist in part
because some of the EGFR markers are prognostic and
associated with trends toward better survival (some
EGFR mutations) or worse survival (high EGFR copy
number). Therefore, it is not possible to assess the ef-
fect of EGFR-TKI therapy on survival in the absence ofPRACTICE GUIDELINE SERIES
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a no-treatment control arm. Furthermore, markers that
seem to predict for a differential survival benefit when
EGFR-TKI therapy is compared with placebo or no treat-
ment may not be predictive when EGFR-TKI therapy is
compared with another form of treatment such as
chemotherapy. As a result, the evidence is currently
insufficient to recommend the routine use of molecu-
lar markers and clinical characteristics to select patients
for therapy with an EGFR-TKI. It is therefore also pre-
mature to recommend the use of single-agent EGFR-TKIs
as first-line therapy for NSCLC, even in patients selected
on basis of molecular and clinical characteristics.
These results highlight the need for prospective tri-
als in which tumour samples are available for all pa-
tients, so as to address correlative questions. Ongoing
research will also address questions concerning the
sequence of platinum-based chemotherapy or EGFR-
TKI as first-line therapy.
Since the literature search for the present review
was completed, preliminary data from two trials of
maintenance gefitinib or erlotinib in Asian populations
were presented at the American Society of Clinical
Oncology Annual Scientific Meeting in 2008 87,88. Both
trials showed improved PFS, but no significant improve-
ments in OS. In addition, initial results of IPASS (Iressa
Pan ASia Study) were presented at the 2008 meeting
of the European Society for Medical Oncology 89. That
trial compared first-line gefitinib with carboplatin and
paclitaxel in light- or never-smoking Asian patients. A
significant improvement was observed in PFS, but no
significant difference in OS. Other ongoing trials are
evaluating the role of an EGFR-TKI as maintenance
therapy in patients responding to first-line platinum-
based chemotherapy.
Lastly, chemotherapy experience suggests that the
therapeutic ratio can be improved with combination
therapy. Preliminary evidence suggests that combina-
tion therapy with an EGFR-TKI and agents active against
vascular endothelial growth factor may have greater
activity. These questions are being addressed in multi-
ple ongoing clinical trials. Participation in these trials
should be encouraged.
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